Letters to the Editor

No Net Effect of Angiotensin II on Blood Pressure?

To the Editor:

With great interest we read the recent study by Carey et al1 on angiotensin (Ang) II type 2 receptor (AT$_2$) receptor–mediated hypotension in anesthetized and conscious rats. These data oppose our findings on the lack of AT$_2$ receptor–mediated systemic hemodynamic effects in anesthetized rats.2 To explain this discrepancy, Carey et al propose that the doses of the Ang II type 1 (AT$_1$) and AT$_2$ receptor antagonists used in our study (irbesartan and PD123319, respectively) were insufficient to unmask AT$_2$ receptor–mediated vasodilation. However, the same doses were high enough to observe AT$_1$ receptor–mediated vasodilation in the rat coronary vascular bed.3 Furthermore, the dose of irbesartan that we used was high enough to fully block the Ang II–induced vasoconstrictor effects in our study, as well as in studies by others.4 Moreover, the PD123319 dose that we used is known to result in micromolar concentrations in blood plasma,5 ie, concentrations that are high enough to selectively block AT$_2$ receptors. Higher doses lead to concentrations that also interfere with AT$_1$ receptors.6

Carey et al mention that AT$_2$ receptors in the adult rat are present in low copy compared with AT$_1$ receptors. In agreement with this concept, exogenous Ang II induces vasoconstriction in the absence of AT$_1$ receptor blockers, and AT$_1$ receptor blockade with either losartan or valsartan results in vasodilation. Unfortunately, the authors did not study the effect of PD123319 alone. If, indeed, Ang II normally has a net vasoconstrictor effect, based on the much larger density of AT$_1$ receptors compared with AT$_2$ receptors, full blockade of both AT$_1$ and AT$_2$ receptors should result in a net decrease in blood pressure. Remarkably, however, the authors observe a normal blood pressure during combined AT$_1$ and AT$_2$ receptor blockade, as if normally Ang II has no net effect on blood pressure.

In this regard, it is important to realize that combined infusions of AT receptor antagonists have been reported to interfere with the effective plasma and tissue levels of the drugs6 and that PD123319 is transformed to a metabolite with AT$_1$ receptor antagonist properties in vivo.7 Thus, pharmacokinetic interactions should be considered when interpreting the data by Carey et al, particularly because these studies lasted several days (thus allowing significant generation of interfering metabolites), and the AT$_2$ receptor–mediated effects in conscious animals became maximal after only 8 days.

Finally, the systemic vasodilation observed by Carey et al with the partial AT$_1$ receptor agonist CGP-42112 is in full agreement with the CGP-42112–induced renal vasodilator responses that were described earlier by Macari et al.8 In the latter study, however, this effect was ascribed to the AT$_1$ receptor–blocking capacity of CGP-42112. The nitric oxide (NO) synthase inhibitor, N$^\bullet$-nitro-L-arginine methylester (L-NAME), reversed the CGP-42112–induced vasodilation, leading Carey et al to suggest that the AT$_2$ receptor–mediated effects depend on NO. However, physiological receptor antagonism, ie, 2 independent opposite effects, cannot be excluded as an explanation for this finding. Furthermore, it is difficult to understand why the authors, in contrast to many previous studies, did not observe a hypertensive effect of L-NAME.

Martin P. Schuijt
Pramod R. Saxena
A.H. Jan Danser
Department of Pharmacology
Erasmus Medical Center
Rotterdam, The Netherlands


Response

We appreciate the interest of Schuijt et al in our paper, “Angiotensin II type 2 receptor–mediated hypotension in angiotensin type-1 receptor–blocked rats.”1 As we stated in our report, several studies have failed to demonstrate AT$_2$ receptor–mediated reduction in blood pressure (BP) in the intact rat. Our explanation for this discrepancy was that these previous studies most likely used much smaller doses of the AT$_2$ receptor blocker, PD 123319, than our study and never demonstrated that PD 123319 fully blocked the AT$_2$ receptor. In our study we used PD 123319 at 50 μg/kg per minute, an infusion rate that blocked specifically the AT$_2$ receptor as demonstrated by its ability to decrease renal production of nitric oxide and eGMP without influencing AT$_1$ receptor activity.2,3 The affinity of PD 123319 for the AT$_2$ receptor is about 17 nmol/L.4–7 Previously, we demonstrated that the AT$_1$ receptor is responsible for prostaglandin E$_2$ (PGE$_2$) release in the kidney1 and that PD 123319 50 μg/kg per minute did not reduce renal PGE$_2$.

Schuijt et al correctly observed that we did not study the effect of PD 123319 alone on BP. However, it had already been demonstrated that PD 123319 enhances the pressor effect of Ang II.8 Previous studies also demonstrated that animals lacking the AT$_2$ receptor exhibit higher BP than their wild-type controls.9–12 Schuijt et al state that PD 123319 is transformed to a metabolite with AT$_1$ receptor antagonist properties. This could happen only
if PD 123319 were used in heroic doses that approach the Ki for the AT₁ receptor at about 100 μmol.¹³ In our study, the PD 123319 infusion rate was <1 μmol/kg per minute, a concentration far below the Ki for the AT₁ receptor.

The concept that full blockade of both AT₁ and AT₂ receptors should result in a net decrease in BP is flawed, because several other compensatory mechanisms would be expected to maintain normal BP.

Concerning the effects of the AT₂ receptor agonist CGP-42112 (CGP), it is known that CGP at large doses (>1000 μg/kg per minute) can cross over to influence the AT₁ receptor. Previous studies reported that both CGP and PD 123319 have a similar Ki for the AT₂ receptor.¹⁴ Macari et al reported that large doses of CGP block¹⁴ and stimulate¹⁵ the AT₁ receptor. Thus, it is very important to limit the CGP dose to less than 1 μmol/L. In our studies the CGP dose was confined within this limitation. Recent studies by Bautista et al¹⁶ confirm this conclusion and clearly show that CGP at 1 μmol/L has renal vasodilator effects through stimulation of the AT₂ receptor.

The AT₁ receptor has a very high affinity for CGP with IC₅₀ of 4+2.2 nmol, whereas AT₁ receptor has a low affinity for CGP with an IC₅₀ of 11.4+1.9 μmol.¹⁷ An approximately 3000-fold difference in affinity exists between the AT₂ and AT₁ receptors for the AT₂-selective agonist CGP. High micromolar concentrations of CGP that completely displace Ang II from AT₁ receptor in response to CGP is not an AT₁-receptor attribute, but rather should be considered an AT₂-receptor–specific phenomenon.¹⁷ All these data confirm the specificity and effects of the AT₂ receptor agonist CGP at the infusion rates employed in our study.

Schuijt et al question why N⁵-nitro-L-arginine methyl ester (L-NAME) did not produce a hypertensive effect. We did not administer L-NAME alone in our study. However, L-NAME did increase BP during CGP administration.

Robert M. Carey  
Nancy L. Howell  
Xiao-Hong Jin  
Helmy M. Siragy  
University of Virginia School of Medicine  
Charlottesville, Virginia


No Net Effect of Angiotensin II on Blood Pressure?
Martin P. Schuitj, Pramod R. Saxena and A.H. Jan Danser

Hypertension. 2002;39:e27-e28
doi: 10.1161/01.HYP.000017852.34860.8F

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/39/5/e27

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/